Editorial
Free Access
Combination chemotherapy for hepatitis B virus: The final solution?
Tim Shaw,
Stephen Locarnini M.D.,
Tim Shaw
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Search for more papers by this authorCorresponding Author
Stephen Locarnini M.D.
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Victorian Infectious Diseases Reference Laboratory, Locked Bag 815, Carlton South, Victoria, 3053, Australia. fax: (61) 3 9342 2666.===Search for more papers by this authorTim Shaw,
Stephen Locarnini M.D.,
Tim Shaw
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Search for more papers by this authorCorresponding Author
Stephen Locarnini M.D.
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
Victorian Infectious Diseases Reference Laboratory, Locked Bag 815, Carlton South, Victoria, 3053, Australia. fax: (61) 3 9342 2666.===Search for more papers by this authorNo abstract is available for this article.
REFERENCES
- 1 Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351–366.MEDLINE
- 2 De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 1999; 12: 81–95.MEDLINE
- 3 Colacino JM, Staschke KA. The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res 1998; 50: 259–322.MEDLINE
- 4 Shaw T, Locarnini SA. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 1995; 15: 169–184.MEDLINE
- 5 Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833–1838.MEDLINE
- 6 Shaw T, Locarnini SA. Combination chemotherapy for HBV: the way forward? Drugs 2000 (in press).
- 7 Nassal M, Schaller H. Hepatitis B virus replication—an update. J Viral Hepat 1996; 3: 217–226.MEDLINE
- 8 Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–1263.MEDLINE
- 9 Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3: 211–215.MEDLINE
- 10 Rayes N, Seehofer D, Bechstein WO, Muller AR, Berg T, Neuhaus R, Neuhaus P. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 1999; 13: 447–452.MEDLINE
- 11 Tassopoullos N, Hadziyannis S, Ideo G, Jurewicz R, Young C, Saltzman R, Trepo C, et al. Famciclovir treatment of anti-HBe+ chronic hepatitis B: Results of a randomized, placebo-controlled study. J Hepatol 2000; 32(Suppl 2): 102.
- 12 Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol 1999; 30: 536–550.MEDLINE
- 13 Hilleman MR. Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different. AIDS Res Hum Retroviruses 1994; 10: 1409–1419.MEDLINE
- 14 Balzarini J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol 1999; 58: 1–27.MEDLINE
- 15 Fontana RJ, Lok AS. Combination therapy for chronic hepatitis B. Hepatology 1997; 26: 234–237.MEDLINE
- 16 Colgrove R, Japour A. A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res 1999; 41: 45–56.MEDLINE
- 17 Clumeck N, De Wit S. Update on highly active antiretroviral therapy: progress and strategies. Biomed Pharmacother 2000; 54: 7–12.MEDLINE
- 18 Romanelli F, Pomeroy C. Human immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals. Pharmacotherapy 2000; 20: 151–157.MEDLINE
- 19 Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670–1677.MEDLINE
- 20 Gunther S, von Breunig F, Santantonio T, Jung MC, Gaeta GB, Fischer L, Sterneck M, et al. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol 1999; 30: 749–754.MEDLINE
- 21 Sallie R. Hepatitis B virus replication and mutation are autoregulated by interactions between surface antigen and HBeAg and the HBV DNA polymerase: a functional model with therapeutic implications. Med Hypotheses 1997; 48: 1–10.MEDLINE
- 22 Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711–1716.MEDLINE
- 23 Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181: 1221–1233.MEDLINE
- 24 Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628–633.MEDLINE
- 25 Ladner SK, Miller TJ, King RW. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother 1998; 42: 2128–2131.MEDLINE
- 26 Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562–568.MEDLINE
- 27 Marques AR, Lau DT, McKenzie R, Straus SE, Hoofnagle JH. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J Infect Dis 1998; 178: 1483–1487.MEDLINE
- 28 Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216–225.MEDLINE
- 29 Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44: 551–560.MEDLINE
- 30 Korba BE, Cote P, Hornbuckle W, Schinazi R, Gerin JL, Tennant BC. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antiviral Res 2000; 45: 19–32.MEDLINE
- 31 Payne RJ, Nowak MA, Blumberg BS. The dynamics of hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93: 6542–6546.MEDLINE
- 32 Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863–1869.MEDLINE
- 33 de Man RA, Marcellin P, Habal F, Desmond P, Wright T, Rose T, Jurewicz R, et al. A randomized, placebo-controlled trial to evaluate the efficacy of twelve-month famciclovir treatment in patients with chronic HBeAg-positive hepatitis B. Hepatology 2000; 32: 413–417.MEDLINE
- 34 Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31: 219–224.MEDLINE
- 35 Lau GKK, Tsiang M, Hou J, Yuen ST, Carmen WF, Zhang L, Gibbs CS, Lam S. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: a viral dynamics study. Hepatology 2000; 32: 394–399.MEDLINE
- 36 Yuen M-F, Ching-Lung L. Debates in hepatitis: how to assess HBV DNA reductions in association with therapy. Viral Hepatitis Rev 1999; 5: 159–175.
- 37 Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38: 702–707.MEDLINE
